Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 565

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 565
---
 $            | (4,891 | ) |     | $ | (1,677 | ) |
| Financing activities                                  |     |              |  4,891 |   |     |   |  1,661 |   |
| Net change in cash and cash equivalents               |     | $            |      — |   |     | $ |    (16 | ) |

**Cash Flows from Operating Activities For the three months ended March 31, 2025, net cash used for operating activities was approximately $0.4 million, attributable to our net loss of $0.7 million, partially offset by stock-based compensation of $0.1 million and changes in operating assets and liabilities that provided $0.2 million of cash. For the three months ended March 31, 2024, net cash used for operating activities was approximately $2.1 million, attributable to our net loss of $1.5 million and changes in operating assets and liabilities that used $0.8 million of cash, partially offset by stock-based compensation of $0.2 million. For the year ended December 31, 2024, net cash used for operating activities was approximately $4.9 million, attributable to our net loss of $4.7 million and changes in operating assets and liabilities that used $0.9 million of cash, partially offset by stock-based compensation of $0.7 million. For the year ended December 31, 2023, net cash used for operating activities was approximately $1.7 million, attributable to our net loss of $3.3 million, partially offset by stock-based compensation of $0.8 million, and changes in operating assets and liabilities that provided $0.8 million of cash. Cash Flows from Financing Activities For the three months ended March 31, 2025, net cash provided by financing activities was $0.4 million and was due to $1.2 million of proceeds related to loans from Scilex, offset by $0.8 million of payments of deferred offering costs. For the three months ended March 31, 2024, net cash provided by financing activities was $2.2 million and was due to proceeds related to loans from Scilex. For the year ended December 31, 2024, net cash provided by financing activities was $4.9 million and was due to $10.9 million of proceeds related to loans from Scilex, offset by $6.0 million of payments